



Citation for published version:

Emery, C, Whittaker, JL, Mahmoudian, A, Lohmander, LS, Roos, EM, Bennell, KL, Toomey, CM, Reimer, RA, Thompson, D, Ronsky, JL, Kuntze, G, Lloyd, DG, Andriacchi, T, Englund, M, Kraus, VB, Losina, E, Bierma-Zeinstra, S, Runhaar, J, Peat, G, Luyten, FP, Snyder-Mackler, L, Risberg, MA, Mobasheri, A, Guermazi, A, Hunter, DJ & Arden, NK 2019, 'Establishing outcome measures in early knee osteoarthritis', *Nat Rev Rheumatol*, vol. 15, no. 7, pp. 438-448. <https://doi.org/10.1038/s41584-019-0237-3>

DOI:

[10.1038/s41584-019-0237-3](https://doi.org/10.1038/s41584-019-0237-3)

Publication date:

2019

Document Version

Peer reviewed version

[Link to publication](#)

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **Establishing outcome measures in early knee osteoarthritis**

2 Carolyn A Emery^{1*}, Jackie L Whittaker², Armaghan Mahmoudian³, L Stefan Lohmander⁴, Ewa M Roos⁵, Kim
3 L Bennell⁶, Clodagh M Toomey⁷, Raylene A Reimer⁸, Dylan Thompson⁹, Janet L Ronsky¹⁰, Gregor Kuntze¹¹,
4 David G Lloyd¹², Thomas Andriacchi¹³, Martin Englund¹⁴, Virginia B Kraus¹⁵, Elena Losina¹⁶, Sita Bierma-
5 Zeinstra¹⁷⁻¹⁹, Jos Runhaar^{18,19}, George Peat^{20,21}, Frank P Luyten²², Lynn Snyder-Mackler²³, May Arna
6 Risberg²⁴, Ali Mobasher^{18,23-26}, Ali Guermazi²⁷, David J Hunter²⁸, Nigel K Arden^{25,29}

7 ¹*Sport Injury Prevention Research Centre, Faculty of Kinesiology and Alberta Children's Hospital Research*
8 *Institute and McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of*
9 *Calgary, Calgary, Canada*

10 ²*Department of Physical Therapy, Faculty of Rehabilitation Medicine, University of Alberta, Edmonton,*
11 *Canada*

12 ³*Division of Rheumatology, Skeletal Biology & Engineering Research Center, University Hospitals KU*
13 *Leuven, Belgium*

14 ⁴*Department of Clinical Sciences Lund, Orthopaedics, Lund University, Lund, Sweden*

15 ⁵*Department of Sports and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark*

16 ⁶*Centre for Health, Exercise and Sports Medicine, University of Melbourne, Melbourne, Australia*

17 ⁷*Sport Injury Prevention Research Centre, Faculty of Kinesiology University of Calgary, Calgary, Canada*

18 ⁸*Faculty of Kinesiology and Department of Biochemistry and Molecular Biology, University of Calgary,*
19 *Calgary, Canada*

20 ⁹*Department for Health, University of Bath, Bath, UK*

21 ¹⁰*Schulich School of Engineering, Faculty of Kinesiology, and McCaig Institute for Bone and Joint Health,*
22 *Cumming School of Medicine, University of Calgary, Calgary, Canada*

23 ¹¹ *Sport Injury Prevention Research Centre, Faculty of Kinesiology and Alberta Children's Hospital*
24 *Research Institute and McCaig Institute for Bone and Joint Health, Cumming School of Medicine,*
25 *University of Calgary, Calgary, Canada*

26 ¹² *Gold Coast Centre for Orthopaedic Research, Engineering and Education (GCORE), Menzies Health*
27 *Institute Queensland, Griffith University, Australia*

28 ¹³ *Department of Mechanical Engineering and Department of Orthopedic Surgery, Stanford University,*
29 *Stanford CA, Palo Alto Veterans Affairs Health Care System, Palo Alto, CA, USA*

30 ¹⁴ *Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund,*
31 *Sweden*

32 ¹⁵ *Duke Molecular Physiology Institute and Division of Rheumatology, Department of Medicine, Duke*
33 *University School of Medicine, Durham, NC, USA*

34 ¹⁶ *The Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Harvard*
35 *Medical School and Boston University School of Public Health, Boston, MA USA*

36 ¹⁷ *Department of Orthopaedics, Erasmus MC - University Medical Center Rotterdam, The Netherlands;*

37 ¹⁸ *D-BOARD Consortium, European Commission Framework 7 programme*

38 ¹⁹ *Department of General Practice, Erasmus MC - University Medical Center Rotterdam, The Netherlands*

39 ²⁰ *Research Institute for Primary Care & Health Sciences, Keele University, Staffordshire, UK*

40 ²¹ *Primary Care Versus Arthritis, UK*

41 ²² *Division of Rheumatology, Skeletal Biology & Engineering Research Center, University Hospitals KU*
42 *Leuven, Belgium*

43 ²³ *Departments of Physical Therapy and Biomedical Engineering, STAR Health, University of Delaware,*
44 *Newark, Delaware, USA*

45 ²⁴*Norwegian Research Center for Active Rehabilitation, Department of Sports medicine, Norwegian School*
46 *Sport Sciences and Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway*

47 ⁵³*Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius,*
48 *Lithuania;*

49 ²⁴*Queen's Medical Centre, Nottingham, UK*

50 ²⁵*Centre for Sport, Exercise and Osteoarthritis Versus Arthritis, UK*

51 ²⁶*APPROACH Consortium, European Commission Innovative Medicines Initiative*

52 ²⁷*Boston University School of Medicine, Boston, USA*

53 ²⁸*Institute of Bone and Joint Research, Kolling Institute, University of Sydney and Rheumatology*
54 *Department, Royal North Shore Hospital, Sydney, Australia*

55 ²⁹*Oxford University, Oxford, UK*

56

57 Email: caemery@ucalgary.ca

58

59

60

61

62 **Abstract**

63 The classification and monitoring of individuals with early knee osteoarthritis (OA) is an important strategy
64 for the design and evaluation of therapeutic interventions. Such an approach requires the identification of
65 appropriate outcomes measures. Potential outcome measures for early OA include patient-reported
66 outcomes (such as measures of pain, function or quality of life), features of clinical examination (such as
67 joint line tenderness and crepitus (that is, grating and crackling sounds), objective measures of physical
68 function, levels of physical activity, movement biomechanics, structural assessments such as magnetic
69 resonance imaging (MRI) and biochemical markers in body fluid. Patient characteristics such as adiposity
70 and biomechanics of the knee could also have relevance to early OA. Importantly, future research is
71 needed to enable the selection of outcome measures that are feasible, reliable, and validated in those at
72 risk of OA and an early knee OA population. In this Perspectives paper, potential outcome measures of
73 individuals with early symptomatic knee osteoarthritis (OA) are discussed, including those that could be
74 of use in clinical practice as well as research settings.

75

76 **[H1] Introduction**

77 Osteoarthritis (OA) is a leading cause of chronic pain, disability, and health care utilization, with knee OA
78 contributing the greatest burden¹⁻⁴. OA is associated with increased rates of comorbidity (for example,
79 obesity and heart disease)¹ and ranks the 13th ² most burdensome amongst all forms of disability world-
80 wide. The incidence, burden and socioeconomic impact of OA is considerable and growing^{3, 5}. Therefore,
81 a shift in the treatment approach is needed from treating patients once they have established OA to a
82 proactive approach that focuses on mitigating risk factors. The classification and monitoring of early OA,
83 on a trajectory from normal to symptomatic and/or radiographic OA, would provide an opportunity in
84 clinical practice and research for the development and evaluation of interventions to prevent or slow down
85 the disease process at a time it is probably more amenable to modification.

86 Although the definition of early OA and appropriate outcomes are under development, OA is probably
87 heterogeneous in terms of its presentation and progression. Knee OA might progress slowly over a period
88 of ten or more years, rapidly, or not at all⁶. Predicting the development and progression of disease through
89 identifying risk factors and mechanisms of OA is important in chronic disease management to inform
90 targeted OA prevention and treatment strategies. This strategy is difficult because of the heterogeneous
91 presentation of OA; however, the availability of increasingly sophisticated statistical and computational
92 methods, microsimulation modelling, and large population-based cohort studies make this approach
93 increasingly viable. For example, widely-used online prediction tools are now available for evaluating
94 future risk of osteoporotic fractures and for guiding clinicians in preventive management of osteoporosis<sup>7-
95 9</sup>. Comparable reliable and validated outcomes for early knee OA will inform the evaluation of risk factors
96 for the progression of early OA. More than one set of risk factors and models will probably be needed to
97 predict early OA in the future. The Rotterdam and Chingford studies (two prospective population-based
98 studies) have demonstrated an ability to predict incident radiographic knee OA using a combination of
99 clinical, genetic, and radiographic factors¹⁰. When performing risk assessment and creating a predictive
100 model for early knee OA, many aspects need to be considered: the definitions of the outcome and
101 prognostic factors; the duration of the clinically relevant prediction period; and the setting in which the
102 risk prediction tool will be used (for example, primary care, secondary care or a research setting). For
103 instance, expensive and intensive predictive tools such as MRI scans and biochemical markers might be
104 restricted to secondary care and/or a research setting.

105 In this Perspectives article, we highlight considerations for best practice in the selection of outcome
106 measures for use in clinical and research settings to evaluate patients at initial presentation of early knee
107 OA across different outcome domains: patient-reported outcomes, clinical examination, physical function,
108 adiposity, physical activity, nutrition, biomechanical outcomes, imaging features and biochemical
109 markers¹¹. We suggest outcome measures that could be considered for use in individuals with early knee
110 OA in clinical care and research settings using published evidence (primarily from post-traumatic and

111 established OA populations), emerging evidence (ongoing studies), and clinical expertise (Box 1). The
112 outcome measures highlighted are relevant to individuals that are at risk of OA and fit the provisional
113 criteria for early knee OA based on patient reported outcomes of pain and function, together with clinical
114 signs (joint line tenderness or crepitus) and a radiographic Kellgren-Lawrence (KL) grade of 0-1¹². Although
115 proposed as important evidence-informed clinical outcome measures, these outcome measures will
116 require additional validation and possible modification to suit local primary care and other healthcare
117 settings, as well as periodical updates.

118

119 [H1] Patient-reported outcomes

120 Patient-reported outcomes are any report of a patient's health status that comes directly from the patient
121 without interpretation by others (for example, the clinician). These measures commonly take the form of
122 a questionnaire. Most relevant patient-reported outcome measures have been developed to either assess
123 individuals with a knee injury (for example, International Knee Documentation Committee 2000
124 (IKDC2000)) or established OA (for example, Western Ontario and McMaster Osteoarthritis Index
125 (WOMAC)); although, one questionnaire has been developed to cover the full spectrum from injury to
126 established OA (the Knee Injury and Osteoarthritis Outcome Score (KOOS)). The relative merits of these
127 and other available instruments that measure self-reported pain, function, and quality of life have been
128 the subject of previous reviews^{13, 14}. Today measures, such as PROMIS, are often developed using
129 computer adaptive strategies which may also prove to be relevant for use in people with early knee OA¹⁵.
130 Many of the considerations that influence the choice of measure in established OA (for example,
131 respondent burden, cost or availability) apply also in early OA.

132 Ultra-brief (one or two domains) unidimensional generic measures, such as the 11-point Numerical Rating
133 Scale (NRS-11), the 36-Item short form health survey (SF-36) bodily pain scale (SF-BP 36), have been
134 recommended in previous reviews for established OA¹⁶ and are probably applicable also in early OA.

135 However, the disadvantage of unidimensional measures is a restricted view of the pain character and
136 intensity^{16, 17}, which is probably inappropriate based on emerging evidence from qualitative studies in
137 patients with early knee OA¹⁸⁻²⁰. For instance, these patients report that their initial symptoms can be
138 experienced as ‘an awareness’ of the knee, loss of confidence, or needing to ‘be careful’ as opposed to
139 ‘pain’. The KOOS knee-related quality of life subscale includes consideration of questions on these
140 aspects^{14,15}. Further, reporting OA pain as ‘constant’ or ‘present on most days’ might give floor effects (i.e.,
141 most individuals may report at the lower end of the scale) in early OA as these patients often report
142 episodic and intermittent pain with certain activities. For example, pain during ascending or descending
143 stairs seemed to be the earliest functional difficulty reported in the OA initiative²¹. Accordingly, the
144 intermittent and constant assessment of pain score (ICOAP) questionnaire, which includes a subscale on
145 intermittent symptoms, has an increasing amount of evidence supporting its’ reliability and validity²².

146 Another important consideration is that the early phase of knee OA is often associated with the emergence
147 of adaptive behaviour. Symptom frequency and intensity might be minimized through the selection of
148 behaviours (for example, performing some activities less often), optimization of behaviours (for example,
149 advanced planning of activities, including anticipatory analgesic use), and compensatory adaptations (for
150 example, modifying the way activities are performed)²³. Therefore, consideration of adaptive behaviour is
151 a legitimate topic for outcome measurement in early OA²⁴, an example of which is the Questionnaire to
152 Identify Knee Symptoms (QuIKS). QuIKS includes questions such as “I am considering stopping a favorite
153 activity due to my knees” and “I am considering changing my exercise routine due to my knee problems”²⁵.

154 The KOOS was developed for self-reporting of patient-relevant outcomes across the lifespan, from time of
155 knee injury and potential knee OA onset to severe OA²⁶⁻²⁹. In five separate subscales this tool assesses
156 perceived pain and other symptoms (e.g., stiffness, grinding, catching), perceived difficulty with function
157 during daily life and sport and recreational activities, and knee-related quality of life. The KOOS
158 measurement properties have been reported in studies of young, middle-aged, and elderly groups with

159 knee injury or OA, and across the spectrum of¹⁴. A comprehensive literature search identified 37 eligible
160 papers evaluating KOOS measurement properties in participants with knee injuries and/or osteoarthritis
161 (OA) and found that KOOS demonstrates adequate content validity, internal consistency, test-retest
162 reliability, construct validity and responsiveness for age- and condition-relevant subscales¹⁴.The KOOS is
163 feasible to administer electronically and in paper form and KOOS scoring instructions and population-
164 based KOOS reference data are available. In addition, longitudinal KOOS data have been collected from
165 more than 100,000 patients in surgical registries of anterior cruciate ligament reconstruction and knee
166 replacement facilitating comparisons to many different populations^{30, 31}. In addition, for the interested
167 researcher, KOOS data are freely available and collected from the cohort of patients who are at increased
168 risk of OA and the cohort of patients with established disease from the NIH-sponsored OA Initiative³². The
169 OA initiative also collects a wide range of other self-reported, clinical and imaging data³². The cohort at
170 risk include people with symptoms and two or more risk factors (including knee injury) but without
171 radiographic OA³².

172 The ICOAP was designed to evaluate the pain experience in people with OA. It includes pain intensity,
173 frequency, and impact on mood, sleep and quality of life. It is intended to be used alongside a measure of
174 physical function²². OA-specific measures developed for more advanced OA cannot be assumed to have
175 adequate psychometric properties when applied to early OA. Yet, the requirement for adequate
176 performance in early OA must be balanced against the benefits for a coherent evidence base that comes
177 from using common measures across the spectrum from early to advanced OA. Of existing measures, the
178 KOOS and ICOAP seem to best strike this balance and are therefore strong candidates for evaluating early
179 knee OA (Box 1), particularly as these instruments focus on different aspects; both have the advantage of
180 being freely available. Published reviews of the psychometric properties of these two measures require
181 systematic updating with specific attention to their performance in early OA.

182 **[H1] Clinical examination outcomes**

183 Clinical examination outcomes are relevant in research and are easy to perform in primary care. Joint line
184 tenderness (tibiofemoral and/or patellofemoral joint lines) at baseline was suggested to be a strong
185 predictor of five-year pain progression (moderate progression adjusted OR=3.9 (95% CI; 2.3 - 6.6)³³ in the
186 CHECK cohort (n=705) that included patients with newly onset knee pain or stiffness³⁴. Several studies
187 have evaluated the ability of physical signs to predict the clinical onset of structural radiographic OA in
188 patients with an increased risk of OA³³⁻³⁷. Data from the HONEUR Study, which included 549 participants
189 who were recruited at the first presentation of knee pain in primary care, suggested that joint line
190 tenderness, crepitus (that is, grating, crackling, popping sounds), pain with passive flexion, and a self-
191 reported swollen knee predicted incident radiographic tibiofemoral knee OA after 6 years³⁵. Using MRI
192 features of knee OA as an outcome measure, data from the general population Rotterdam Study showed
193 that joint line tenderness together with the 'feeling of giving way' were associated with the incidence of
194 tibiofemoral knee OA, whereas crepitus was identified as a good predictor of patellofemoral OA^{36, 37}.

195 Easily assessable measures from physical examination might be associated with future OA development,
196 including joint line tenderness and crepitus, even in the absence of radiologic findings of OA (Box 1).
197 Clinical examination of these features had good inter-observer reliability in a population with evident knee
198 osteoarthritis if a standardised approach to such assessment is used³⁸. However, these clinical assessment
199 components require further examination of reliability and validation for research settings in early knee OA
200 and standardization for use in clinical settings.

201 **[H1] Physical function outcomes**

202 Given that the early pre-radiographic stage of OA is associated with intermittent symptoms and adaptive
203 physical behaviour, the clinical evaluation of patients with, or at risk of, early knee OA should incorporate
204 robust outcome measures of physical function³⁹. Currently, no consensus exists regarding which outcomes
205 are most relevant for use in this population. For the purposes of this Perspective article, physical function
206 is operationally defined as 'physiological functions' or 'the ability to move around and to perform daily

207 activities' that can be classified as 'body functions and structure' or 'activities and participation',
208 respectively, using the World Health Organization International Classification of Functioning, Disability and
209 Health (ICF) model⁴⁰. As physical function is multi-dimensional, both performance-based and physical
210 impairment measures (which might require specialized pieces of equipment and raters) are discussed in
211 this section. Emerging evidence suggest that some of these outcome measures might be suitable for the
212 evaluation of early OA and those at risk of OA (Table 1)⁴¹⁻⁴⁶.

213 A range of performance-based measures are available although the degree to which their measurement
214 properties are established and the range of populations they have been used in varies (Table 1). Measures
215 that have undergone fairly extensive investigation include the Single Leg Hop for distance test^{43, 44, 47-50}, the
216 Cross Hop for distance^{43, 47-51}, the 6-meter Timed Hop Test^{43, 47-50}, the Star Excursion and similar Y-balance
217 Btest^{44, 51-56}, the 30-second Chair Sit-to-Stand Test⁵⁷⁻⁵⁹, and the 6-minute walk test^{41, 42}, while there is
218 emerging evidence for the Vertical Drop Jump^{44, 60}, the Single Leg Squat^{44, 61-63}, Unipedal Dynamic Balance
219 test^{44, 64} and 20-meter Shuttle Run^{44, 65}. The most commonly reported outcome of physical impairment is
220 quadriceps muscle strength^{44, 47, 48, 52, 66}, however, there may also be value in considering the strength of
221 other lower extremity muscles including the hamstring, hip abductor and hip adductor muscles⁶⁷;
222 although, insufficient information is available to advocate for specific contraction mode (i.e., isotonic,
223 isokinetic or isometric) or type (i.e., concentric or eccentric).

224 Because of floor and ceiling effects (i.e., most individuals report a minimum – floor, or maximum – ceiling
225 score), separate measures are required to cover the wide range of ages and abilities of patients with early
226 knee OA in both clinical and research settings . Functional outcomes that should be considered for use in
227 research and in clinical physical and exercise therapy practice based on their measurement properties and
228 ability to span the full spectrum of patient age and abilities include the Single Leg Hop for distance, 30-
229 second Chair Sit-to-Stand Test, 6-minute walk test, Star Excursion Balance Test and a quadriceps strength
230 measure. The performance-based outcomes should be administered in a standardized, validated and

231 reproducible fashion to enable detection of change over time; video demonstrations and explicit
232 instructions for standardized testing are available online (see related links). Further research validating
233 functional outcomes in ‘at risk’ (e.g., intra-articular knee injury, obesity, varus/valgus alignment
234 abnormality) and ‘early-OA’ populations is required and this research should inform the periodic updating
235 of these suggested functional outcomes.

236

237 **[H1] Modifiable lifestyle-related outcomes**

238 The presence of modifiable risk factors related to lifestyle, such as obesity, dietary inadequacies, and
239 physical inactivity might lead to accelerated disease onset and progression through a combination of
240 mechanical and systemic mechanisms⁶⁸. Identifying these modifiable risk factors in early knee OA is
241 important for the prevention of OA.

242 Several measures of adiposity or weight have been studied in established OA, but less so in early OA. These
243 include BMI, waist-height ratio (WHR) and waist circumference⁶⁹⁻⁷³. The location of fat deposits influences
244 their metabolic and inflammatory potential and therefore may be important considerations⁷⁴. A high
245 waist-height ratio or waist circumference (indicative of abdominal adiposity) was associated with an
246 increased risk of OA progression⁷³; however, neither outcome was associated with the loss of tibial or
247 patellar cartilage volume or defects in adults in the community with pre-radiographic OA^{75, 76}. To better
248 understand this relationship, a distinction between subcutaneous and visceral adiposity using valid
249 assessment techniques (e.g. MRI or CT assessment) is likely needed. Measurements of fat mass (kg),
250 percentage fat mass (percentage of total mass) and fat mass index (FMI; fat mass/height²), can be obtained
251 using dual-energy x-ray absorptiometry or bioelectrical impedance analysis, hence permitting a direct
252 measure of total adiposity⁷⁷. Total fat mass is positively associated with an increased risk of knee cartilage
253 defects and the presence of bone marrow lesions in healthy individuals (aged 25-60 years)⁷⁸ and medial
254 tibiofemoral cartilage volume loss over 2-10 years in adults aged 51-81 years^{79, 80}. A systematic review

255 reported moderate evidence for the relationship between obesity (that is, increasing weight, BMI or total
256 body fat mass) and the presence of bone marrow lesions in the knee in individuals with OA⁷². In addition
257 to contributing to an increased mechanical load, adiposity is thought to have a metabolic and pro-
258 inflammatory function in OA; therefore, a direct measure of adiposity such as fat mass, percentage fat
259 mass or FMI might be useful in the assessment of early-stage OA⁸¹⁻⁸⁴.

260 Physical activity is a modifiable outcome that might delay the onset of functional limitation, prevent
261 obesity, and is essential for normal joint health⁸⁵. In addition, physical activity can reduce pain and
262 disability among individuals with OA and increase their physical performance and self-efficacy⁸⁶⁻⁸⁸. Light or
263 moderate intensity physical activity might protect against the onset of disability related to symptomatic
264 OA, whereas a sedentary lifestyle or high levels of strenuous physical activity are considered risk factors<sup>89-
265 91</sup>. Many variations of self-reported measures of physical activity exist including global or short recall
266 questionnaires, although most have limited accuracy⁸⁹⁻⁹¹. Wearable monitors that measure body motion
267 can be used to assess physical activity and energy expenditure. The most commonly used sensor, validated
268 across multiple populations, is an accelerometer (for example, Actigraph)⁹², which captures frequency,
269 intensity, and duration of physical activity in a time-stamped manner. The large selection of off-the-shelf
270 accelerometers, often contained in mobile phones, might be more suitable in a primary care setting to
271 measure physical activity as they are less expensive, easier to use, and widely available^{93, 94}. Most
272 accelerometers, however, are not validated to measure cycling or swimming. In general, objective
273 measures of physical activity such as accelerometer outcomes compared with self-reporting have stronger
274 relationships with function in OA⁹⁵ and are a more accurate assessment of physical activity and sedentary
275 lifestyle.

276 Nutrition interventions such as weight loss^{96, 97} are lifestyle-related changes that can potentially improve
277 OA symptoms. Beyond the link between obesity and knee OA (and therefore the important contribution
278 of weight loss)^{98, 99}, the contribution of nutritional factors is an emerging and important area of research,

279 although limited clinical evidence is available to date. For example, low dietary intakes of fibre¹⁰⁰ or omega-
280 3 polyunsaturated fatty acids¹⁰¹, and high fat diets¹⁰² are risk factors for OA and/or worsening of pain in
281 OA and might therefore warrant monitoring in early OA. Many of the nutrients or dietary patterns tested
282 to date probably contribute to pathology via alterations in body weight or inflammation, although the
283 direct effects of these factors requires further investigation. The tools to monitor dietary intake are
284 numerous (for example, the Food Frequency Questionnaire (FFQ), 24-hour dietary recall (either the paper-
285 based or web-based automated self-administered 24-hour dietary recall (ASA24) assessment tools¹⁰³) and
286 the 3-day or 7-day weighed food record) and need to be assessed for each clinical or research setting. In
287 addition, tools to assess adherence to diets that reduce inflammation such as the Mediterranean Diet
288 Adherence Screener¹⁰⁴ might also warrant use in future.

289 Hence, objective measures of adiposity are desirable. BMI is a useful outcome measure for assessing
290 adiposity in a primary clinical setting because of its familiarity, validity, and reference ranges. However,
291 BMI has limitations for use in young athletes. Although weight loss can improve OA symptoms, further
292 research is needed to identify a means of assessing important OA-related nutritional factors. Assessment
293 of physical activity using a validated accelerometer, to accurately capture activity through each domain
294 and intensity, is a promising area that requires future study.

295

296 **[H1] Biomechanical outcomes**

297 Biomechanical outcomes are measures of joint mechanics typically collected in a research setting, but
298 sometimes taken in a primary care setting. Joint mechanics can be employed to assess OA severity, but
299 also for understanding the causes of OA onset and progression. For example, altered joint mechanics
300 following knee injury might contribute to the onset and development of post-traumatic OA³⁹. Indirect
301 evidence to support this concept comes from observations of altered joint movement, loading, and muscle
302 activation patterns following injury¹⁰⁵⁻¹¹⁰, with radiographic knee OA (KL \geq 2)¹¹¹⁻¹¹³, with aging^{114, 115} and pre

303 and post joint arthroplasty¹¹⁶⁻¹¹⁸. Abnormal joint alignment^{119,120}, alteration of the external knee adduction
304 moment (KAM) and increased varus alignment are often regarded as indicators of altered joint mechanics
305 associated with increased OA severity¹¹³. However, joint mechanics in OA might also change because of
306 other factors including loss of dynamic joint stability^{121, 122}, muscle atrophy¹²³, neuromuscular inhibition¹²⁴,
307 muscle weakness,¹²⁵⁻¹²⁷ and compensatory muscle activation mechanisms^{111, 112, 117}. These changes might
308 alter cartilage loading and contact mechanics. Indeed, some studies indicate that changes in tibiofemoral
309 cartilage contact locations^{39, 128}, elongated path lengths¹²⁹, force magnitudes^{106, 130, 131}, and deformations^{128,}
310 ¹²⁹ are associated with OA onset and progression. In turn, OA progression might be caused by progressive
311 degradation of cartilage through interactions of articular movement and cartilage loading abnormalities,
312 chronic inflammation, resultant tissue remodelling, and other OA risk factors by increasing the
313 susceptibility of cartilage and subchondral bone to damage and degradation at regions inadequately
314 adapted to these altered loads^{128, 132-136}. Over time, this process might result in altered cartilage thicknesses
315 and clinically relevant cartilage thinning in different regions of the articular cartilage surfaces . To verify
316 this mechanism, longitudinal data are needed of the joint mechanics, cartilage thickness, and cartilage
317 structure and integrity in OA^{137, 138}. Integration of this information with other risk factors for OA-related
318 changes might inform the development of novel patient-specific, diagnostic or predictive models to aid in
319 early patient screening, intervention efficacy monitoring, and the development of new therapeutics^{130, 131,}
320 ^{133, 139, 140}. Armed with these data and models, new wearable monitors might enable biomechanical
321 outcomes assessment in the clinic and community^{134-136, 141, 142}, and might provide the possibility of
322 developing and monitoring personalized treatment plans.

323 Presently, the joint range of motion is a suggested measure that could be collected in a primary care setting
324 to assess OA severity. The other biomechanical outcomes mentioned above (e.g., KAM, kinematics,
325 electromyography, cartilage loading) although used to understand the mechanisms of OA progression and
326 currently not feasibly collected in most clinical settings, are an important component for consideration in

327 research settings to inform orthotics design, exercise interventions, bracing, and surgical interventions. In
328 the future, validated wearable monitors might help assess biomechanical outcomes of early interventions
329 in the clinic and community. Evidence suggest that outcome measures are not independent but rather
330 variation in one outcome measure (for example, biomechanical outcomes) can influence the quantitative
331 state of another measure (for example, biochemical markers or imaging outcomes)¹⁴³⁻¹⁴⁷. Thus, future
332 research should consider the interaction between different outcome measures to potentially increase the
333 sensitivity of detecting early OA^{132, 144}.

334 **[H1] Imaging outcomes**

335 OA is a complex syndrome that at the local level, is best characterised as a whole joint disease involving
336 multiple tissue pathologies. In attempting to characterise and monitor the variety of OA structural
337 components a number of different imaging modalities have been used-the most common amongst
338 these being radiography, ultrasound and MRI. This section will predominantly focus on plain
339 radiography and MRI, as ultrasound has a number of limitations that have constrained its development
340 and validity in this area including observer dependency its' inability to assess bone marrow lesions and
341 to adequately image deep articular joint structures including meniscus and cartilage¹⁴⁸.

342 MRI plays a major role in the OA research setting, with compositional MRI techniques becoming
343 increasingly more important due to their capacity to assess 'pre-morphologic' biochemical compositional
344 changes of articular and periarticular tissues. Although radiography remains the primary imaging modality
345 in OA clinical trials and in daily medical practice, known limitations for visualisation of OA features
346 significantly limits the utility of radiography both clinically and in the research arena. Ultrasound can be a
347 useful adjunct to radiography and MRI particularly for the evaluation of synovitis. Emerging hybrid imaging
348 techniques including PET/MRI and PET/CT allow evaluation of the joint with simultaneous assessment of
349 morphological changes and metabolic activities, showing a potential for these hybrid systems to play an
350 increasing role in OA research and clinical practice¹⁴⁹.

351 Radiographic features of OA are generally classified by the Kellgren and Lawrence (KL) grading system¹⁵⁰
352 and include joint space narrowing, osteophyte formation, sclerosis, and deformity of bony contours¹⁵¹.
353 Minimum radiographic joint space width (JSW) is the gold standard recommended by the FDA for detecting
354 structural changes in patients with knee OA in clinical trials. However, standardized measures of
355 radiographic positioning and fixed location JSW width failed to reach the same degree of responsiveness
356 in knee OA as quantitative measures of cartilage thickness on MRI¹⁵². Indeed, fixed-location radiographic
357 measures appear not capable of determining the spatial distribution of femorotibial cartilage loss ¹⁵².
358 Moreover, radiographic features such as loss of joint space, sclerosis, and deformity of bone are associated
359 with late-stage OA and are preceded and detected with greater sensitivity by MRI¹⁵³.

360 Conventional MRI enables the evaluation of morphological changes related to early OA, including but not
361 limited to cartilage damage, meniscal damage, synovitis, presence of BMLs, and ligamentous damage. In
362 one study of patients with knee pain (n=255, age 40-79 years), BMLs were present in 11% of individuals
363 without radiographic OA (KL = 0), 38% of individuals with pre-radiographic OA (KL = 1) and 71% of
364 individuals with radiographic OA (KL >2)^{153, 154}. Similarly, 42% of patients with a diagnosis of symptomatic
365 OA without radiographic features (KL < 2) had BMLs and 57% had cartilage loss¹⁵⁵. Although a paucity of
366 data exists regarding the timeline of structural changes in the period between a joint injury sustained in
367 youth and the onset of clinical post-traumatic OA, advanced MRI techniques have been used to detect
368 subtle cartilage damage at the time of ACL injury¹⁵⁶. Furthermore, macroscopic cartilaginous changes, the
369 presence of BMLs, and bone morphology changes might be detectable by conventional MRI techniques
370 as early as two years post ACL reconstruction or other intra-articular knee injury (and potentially before
371 the development of radiographic OA^{6, 157-160}.

372 In 2011, a definition of MRI-defined OA was proposed to facilitate earlier detection of OA (Box 2)^{161, 162}. In
373 one study of patients who had undergone anterior cruciate ligament (ACL) reconstruction, 19% and 17%
374 of the participants met the MRI criteria for tibiofemoral and patellofemoral OA, respectively, at 1 year¹⁶³.

375 Using the same criteria for MRI-defined OA in patients who participated in a clinical trial of ACL
376 reconstruction, 31% had tibiofemoral OA and 9% patellofemoral OA, respectively, at 5 years¹⁶⁴.
377 Importantly, some of the changes included in this criteria are undetectable by radiography (i.e. cartilage
378 thickness, bone marrow lesions). Different methodologies can be used to measure structural changes in
379 the knee by MRI including the use of semi-quantitative measures (such as the MRI Osteoarthritis Knee
380 Score (MOAKS)), quantitative measures (including cartilage thickness, bone marrow lesion volume,
381 effusion-synovitis volume and meniscal extrusion) and measures obtained using compositional imaging
382 modalities of cartilage (including T2 mapping, T1ρ mapping, delayed gadolinium-enhanced MRI of cartilage
383 (dGEMRIC), sodium MRI and glycosaminoglycan chemical exchange saturation transfer (gagCEST)) which
384 measure cartilage composition and quality¹⁶⁵. Semiquantitative MRI evaluation can be performed using
385 several available scoring systems such as the MRI Osteoarthritis Knee Score (MOAKS) and the Anterior
386 Cruciate Ligament Osteoarthritis Score (ACLOAS)^{154, 166}. For synovitis assessment, contrast-enhanced MRI
387 should be used and semi-quantitative scoring systems based on contrast-enhanced MRI are available to
388 enable clear delineation of the synovium from effusion¹⁶⁷. In population-based studies, a high proportion
389 of radiographically normal knees have osteophytes and cartilage damage detectable by MRI illustrating
390 the greater sensitivity of MRI as compared to radiography¹⁵³. However, it also highlights the challenge of
391 what is to be regarded as OA and what is part of a normally ageing joint¹⁶⁸. The link between anatomical
392 evidence of OA and patients' symptoms and function is still rather weak^{169, 170}. Ultimately, the presence of
393 these findings on MRI require validation by longitudinal follow-up studies to identify their association with
394 subsequent illness related to OA (alteration of patient function and symptoms)¹⁷¹ to avoid over-diagnosis
395 because of incidental MRI findings^{153, 154, 172-174}. Notably, the distinction between pathology and normal
396 features of the ageing joint is unclear and further research to elucidate the clinical relevance of MRI
397 findings in early knee OA is warranted.

398 Hence, the utility of plain radiography in early OA is limited as only relatively late OA changes are
399 detectable. As technology improves, assessing changes in bone shape or trabecular bone texture of sub-
400 chondral bone might be of use. MRI has superior sensitivity to change and validity in the context of early
401 OA¹⁵³. Although not appropriate for all primary care settings because of the high cost and risk of over-
402 diagnosis, MRI is a critical component of ongoing outcome validation research in early knee OA.

403

404 **[H1] Biochemical marker outcomes**

405 Biochemical markers of joint tissue turnover can reflect disease-relevant biological activity that might
406 precede structural changes detectable on plain radiographs or even by MRI. Markers detected in blood,
407 urine or synovial fluid may be associated with or predictive of incident radiographic OA. Some biochemical
408 markers detectable in blood, urine or synovial fluid are associated with or predictive of incident
409 radiographic OA. Ideally, biochemical markers of early OA must clearly differentiate between normal
410 (physiological) and pathological tissue turnover as well as between the early stages of the disease and
411 more advanced joint destruction. Biochemical markers must also be unaffected by other disorders and be
412 easily and consistently measurable in a clinical setting¹⁷⁵. Biochemical markers of early OA might therefore
413 be used to identify pre-radiographic changes at the molecular level, facilitate OA drug discovery, and
414 potentially enable a more rational and personalized approach to healthcare related OA management by
415 prompting earlier and more targeted treatments and interventions¹⁷⁶.

416 Studies of incident OA have identified some of the earliest molecular abnormalities associated with OA
417 and therefore provide biochemical marker candidates for early OA identification. Serum protein
418 signatures using antibody-based protein microarrays have been shown to detect early radiographic hand
419 or knee OA. Four serum proteins (matrix metalloproteinase-7, IL-15, plasminogen activator inhibitor-1
420 and soluble vascular adhesion protein-1) were found to be altered in a cohort of patients with OA
421 compared to healthy individuals¹⁷⁷. Similarly, serum COMP (sCOMP) and hyaluronan concentrations

422 could predict¹⁷⁸ incident knee joint space narrowing and osteophyte (sCOMP) formation 7 years later in
423 another patient cohort. In another study, incident radiographic knee OA (based on KL scores) over ten
424 years was predicted by high serum COMP concentration (based on KL scores) but low serum aggrecan
425 concentration at the beginning of the study¹⁷⁹. Notably, though, molecular and structural biomarkers of
426 inflammation at two years after an acute ACL injury did not predict structural knee osteoarthritis at five
427 years¹⁶⁴. Mean baseline serum osteocalcin concentrations are associated with 3-year incident
428 radiographic hand OA (KL >2) but not knee OA in pre-menopausal and peri-menopausal women¹⁸⁰.
429 Bioactive lipids are also potential biochemical markers of pain and inflammation¹⁸¹ and metabolomics
430 has been used to identify metabolic profiles that can differentiate between synovium samples from
431 patients with OA and healthy individuals¹⁸².
432 In 2006, the NIH-funded OA Biomarkers Network and the OARSI Clinical Trials Biomarkers Working group
433 proposed a new classification system for OA biochemical markers termed BIPEDS^{183, 184}. The purpose of
434 this classification was to clarify the intended primary use of the biochemical marker to reflect Burden of
435 OA disease, Investigative, Prognostic for OA development, Efficacy of OA intervention, Diagnostic for OA
436 and Safety of intervention biochemical markers classification system for OA biochemical markers^{183, 184}.
437 However, a systematic review performed in 2010 concluded that individual biochemical markers and
438 categories of biochemical markers, including their nature, origin and metabolism, need further
439 investigation and validation¹⁸⁵. In 2016, the FDA-NIH Biomarker Working Group published the BEST
440 (Biomarkers, EndpointS, and other Tools) glossary¹⁸⁶. The BEST resource aims to distinguish between
441 biochemical markers and clinical assessments and to describe the distinct functions of biochemical
442 markers in biomedical research, clinical practice, and medical product development. Harmonization of key
443 terms by BEST avoids inconsistent use of key terms that can hinder the evaluation and interpretation of
444 scientific evidence. BEST can thereby be expected to facilitate all aspects of biochemical marker work
445 including testing, validation, commercialization, and perhaps even development for early OA.

446 Biochemical and molecular profiling of biological fluids (for example, serum, plasma and synovial fluid) and
447 joint tissues can provide a global view of the physiologic state of an OA joint. Refinements in omics
448 approaches and advances in analytical platforms and technologies will enable improved profiling of
449 different stages of disease. To be clinically useful these biochemical markers need to be properly qualified
450 (qualification is a regulatory process that links a biochemical marker with biomechanical and/or clinical
451 outcomes) for early OA and they must adhere to the BEST guidelines to be effectively used in a clinical
452 setting, rather than in an exploratory and hypothesis testing research setting.

453 Soluble biochemical markers require further study, validation, and qualification as susceptibility or risk
454 outcomes for the development of early OA before being adopted for widespread use in the clinical care
455 setting.

456

457 **[H1] Conclusions**

458 Various outcome domains exist that could be assessed for patients with early knee OA in research and/or
459 clinical settings, including patient-reported outcomes, clinical features, measures of physical function,
460 adiposity, physical activity or nutrition and biomechanical, imaging, or biochemical markers. Promising
461 patient reported outcomes for this purpose include the KOOS and the ICOAP. Measures of physical
462 outcomes (for example, single leg hop, quadriceps strength) and fat mass index (DXA) are also valid and
463 reliable. With increasing popularity worldwide, a validated wearable physical activity monitor for
464 quantifying levels of physical activity and a 3-day weighed food record for nutritional intake (for example,
465 calories) has potential. MRI-defined OA and biochemical markers, although promising, require specific
466 healthcare and research facilities where the assessment of these outcomes is possible and body fluids can
467 be collected, stored and measured according to standard operating procedures. Additional considerations
468 of patient-preferences and psychosocial outcomes are also important in future research examining early
469 knee OA outcome measures¹⁸⁷. In this regard, further patient-engaged research is recommended.

470 Importantly, multiple factors must be considered to facilitate risk assessment and the development of
471 predictive models for early knee OA. Furthermore, definitions are needed for the potential outcomes,
472 exposures, confounding and effect-modifying variables, duration of the clinically relevant prediction
473 period and the setting in which the risk prediction tool will be used. As such, further research validating
474 outcomes in individuals 'at risk' of early OA progression (for example, individuals with an intra-articular
475 knee injury and/or who are obese) and 'early-OA' populations is required.

476

477 REFERENCES

- 478 1. Suri P, Morgenroth DC, Hunter DJ. Epidemiology of osteoarthritis and associated comorbidities.
479 *PM&R*.4,5,S10-S9 (2012)
- 480 2. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years
481 (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global
482 Burden of Disease Study 2010. *The Lancet*.380,9859,2197-223 (2013)
- 483 3. Bombardier C, Hawker G, Mosher D. The impact of arthritis in Canada: today and over the next 30
484 years. Arthritis Alliance of Canada 2011:
- 485 4. Wright EA, Katz JN, Cisternas MG, Kessler CL, Wagenseller A, Losina E. Impact of knee osteoarthritis on
486 health care resource utilization in a US population-based national sample. *Med Care*.48,9,785-91 (2010)
- 487 5. Losina E, Walensky RP, Reichmann WM, Holt HL, Gerlovin H, Solomon DH, et al. Impact of obesity and
488 knee osteoarthritis on morbidity and mortality in older Americans. *Annals of Internal
489 Medicine*.154,4,217-26 (2011)
- 490 6. Whittaker JL, Toomey CM, Woodhouse LJ, Jaremko JL, Nettel-Aguirre A, Emery CA. Association
491 between MRI-defined osteoarthritis, pain, function and strength 3–10 years following knee joint injury in
492 youth sport. *Br J Sports Med*.bjsports-2017-097576 (2017)
- 493 7. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX WHO Fracture Risk
494 Assessment Tool UK: University of Sheffield; 2011 [cited 2015 16/11/2015].
495 <https://www.shef.ac.uk/FRAX/tool.jsp>].
- 496 8. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk
497 of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study.
498 *BMJ*.344,e3427 (2012)
- 499 9. Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton J, Nicholson W, et al. Screening to Prevent
500 Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services
501 Task Force. *JAMA*.319,24,2532-51 (2018)
- 502 10. Kerkhof H, Bierma-Zeinstra S, Arden N, Metrustry S, Castano-Betancourt M, Hart D, et al. Prediction
503 model for knee osteoarthritis incidence, including clinical, genetic and biochemical risk factors. *Annals of
504 the Rheumatic Diseases*.73,12,2116-21 (2014)
- 505 11. Roemer FW, Kwoh CK, Hayashi D, Felson DT, Guermazi A. The role of radiography and MRI for
506 eligibility assessment in DMOAD trials of knee OA. *Nature Reviews Rheumatology*.14,6,372-80 (2018)
- 507 12. Luyten F, Bierma-Zeinstra S, Dell'Accio F, Kraus V, Nakata K, Sekiya I, et al. Toward classification
508 criteria for early osteoarthritis of the knee. *Seminars in Arthritis and Rheumatism*.47,4,457-63 (2017)
- 509 13. Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM. Measures of knee function: International Knee
510 Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis
511 Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form
512 (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale,
513 Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC),
514 Activity Rating Scale (ARS), and Tegner Activity Score (TAS). *Arthritis Care & Research*.63,S11,S208-S28
515 (2011)
- 516 14. Collins N, Prinsen C, Christensen R, Bartels E, Terwee C, Roos E. Knee Injury and Osteoarthritis
517 Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. *Osteoarthritis
518 and Cartilage*.24,6,1317-29 (2016)
- 519 15. Broderick JE, Schneider S, Junghaenel DU, Schwartz JE, Stone AA. Validity and reliability of patient-
520 reported outcomes measurement information system instruments in osteoarthritis. *Arthritis care &
521 research*.65,10,1625-33 (2013)
- 522 16. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual analog scale for pain (vas
523 pain), numeric rating scale for pain (nrs pain), mcgill pain questionnaire (mpq), short-form mcgill pain

524 questionnaire (sf-mpq), chronic pain grade scale (cpgs), short form-36 bodily pain scale (sf-36 bps), and
525 measure of intermittent and constant osteoarthritis pain (icoap). *Arthritis Care & Research*.63,S11,S240-
526 S52 (2011)

527 17. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome
528 measures for chronic pain clinical trials: IMMPECT recommendations. *Pain*.113,1,9-19 (2005)

529 18. Gooberman-Hill R, Woolhead G, MacKichan F, Ayis S, Williams S, Dieppe P. Assessing chronic joint
530 pain: lessons from a focus group study. *Arthritis Care & Research*.57,4,666-71 (2007)

531 19. Hawker G, Stewart L, French M, Cibere J, Jordan J, March L, et al. Understanding the pain experience
532 in hip and knee osteoarthritis—an OARSI/OMERACT initiative. *Osteoarthritis and Cartilage*.16,4,415-22
533 (2008)

534 20. Maly MR, Cott CA. Being careful: a grounded theory of emergent chronic knee problems. *Arthritis
535 Care & Research*.61,7,937-43 (2009)

536 21. Hensor E, Dube B, Kingsbury SR, Tennant A, Conaghan PG. Toward a Clinical Definition of Early
537 Osteoarthritis: Onset of Patient-Reported Knee Pain Begins on Stairs. Data From the Osteoarthritis
538 Initiative. *Arthritis Care & Research*.67,1,40-7 (2015)

539 22. Hawker G, Davis A, French M, Cibere J, Jordan J, March L, et al. Development and preliminary
540 psychometric testing of a new OA pain measure—an OARSI/OMERACT initiative. *Osteoarthritis and
541 Cartilage*.16,4,409-14 (2008)

542 23. Gignac MA, Cott C, Badley EM. Adaptation to disability: applying selective optimization with
543 compensation to the behaviors of older adults with osteoarthritis. *Psychology and Aging*.17,3,520-4
544 (2002)

545 24. Morden A, Jinks C, Ong BN. Lay models of self-management: how do people manage knee
546 osteoarthritis in context? *Chronic Illness*.7,3,185–200 (2011)

547 25. Clark JM, Chesworth BM, Speechley M, Petrella RJ, Maly MR. Questionnaire to Identify Knee
548 Symptoms: Development of a Tool to Identify Early Experiences Consistent With Knee Osteoarthritis.
549 *Physical Therapy*.94,1,111-20 (2014)

550 26. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynon BD. Knee Injury and Osteoarthritis Outcome
551 Score (KOOS)--development of a self-administered outcome measure. *J Orthop Sports Phys Ther*.28,2,88-
552 96 (1998)

553 27. Örtqvist M, Roos EM, Broström EW, Janarv P-M, Iversen MD. Development of the knee injury and
554 osteoarthritis outcome score for children (KOOS-Child) comprehensibility and content validity. *Acta
555 Orthopaedica*.83,6,666-73 (2012)

556 28. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS)-validation and
557 comparison to the WOMAC in total knee replacement. *Health Qual Life Outcomes*.1,1,17 (2003)

558 29. Roos EM, Roos H, Ekdahl C, Lohmander L. Knee injury and Osteoarthritis Outcome Score (KOOS)-
559 validation of a Swedish version. *Scandinavian Journal of Medicine & Science in Sports*.8,6,439-48 (1998)

560 30. Paradowski PT, Bergman S, Sundén-Lundius A, Lohmander LS, Roos EM. Knee complaints vary with
561 age and gender in the adult population. Population-based reference data for the Knee injury and
562 Osteoarthritis Outcome Score (KOOS). *BMC Musculoskeletal Disorders*.7,1,38 (2006)

563 31. Williamson T, Sikka R, Tompkins M, Nelson BJ. Use of the Knee Injury and Osteoarthritis Outcome
564 Score in a Healthy United States Population. *Am J Sports Med*.44,2,440-6 (2015)

565 32. NIH. NIMH Data Archive: The Osteoarthritis Initiative: National Institute of Health/USA.gov; [cited
566 2019]. This data repository provides access to the data and images from the eleven year OAI longitudinal
567 cohort study.]. Available from: <https://nda.nih.gov/oai>.

568 33. Bastick A, Wesseling J, Damen J, Verkleij S, Emans P, Bindels P, et al. Defining knee pain trajectories in
569 early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective
570 cohort study (CHECK). *The British journal of general practice : the journal of the Royal College of General
571 Practitioners*.66,642,e32-9 (2016)

- 572 34. Wesseling J, Dekker J, Van den Berg W, Bierma-Zeinstra S, Boers M, Cats H, et al. CHECK (Cohort Hip
573 and Cohort Knee): similarities and differences with the Osteoarthritis Initiative. *Annals of the Rheumatic*
574 *Diseases*.68,9,1413-9 (2009)
- 575 35. Kastelein M. **Traumatic and Non-traumatic Knee Complaints in General Practice: Erasmus MC:**
576 *University Medical Center Rotterdam*; 2013. 978-94-6191640-2
- 577 36. Schiphof D, Waarsing E, Oei E, Bierma-Zeinstra S. Crepitus, joint line tenderness and the feeling of
578 giving way are predictive signs for early knee osteoarthritis. *Osteoarthritis and Cartilage*.23,A330 (2015)
- 579 37. Schiphof D, van Middelkoop M, de Klerk BM, Oei EH, Hofman A, Koes BW, et al. Crepitus is a first
580 indication of patellofemoral osteoarthritis (and not of tibiofemoral osteoarthritis). *Osteoarthritis*
581 *Cartilage*.22,5,631-8 (2014)
- 582 38. Maricar N, Callaghan MJ, Parkes MJ, Felson DT, O'Neill TW. Interobserver and Intraobserver
583 Reliability of Clinical Assessments in Knee Osteoarthritis. *J Rheumatol*.43,12,2171-8 (2016)
- 584 39. Andriacchi TP, Mundermann A, Smith RL, Alexander EJ, Dyrby CO, Koo S. A framework for the in vivo
585 pathomechanics of osteoarthritis at the knee. *Annals of Biomedical Engineering*.32,3,447-57 (2004)
- 586 40. World Health Organization. International classification of functioning, disability and health: ICF.
587 Geneva, Switzerland: World Health Organization; 2001.
- 588 41. Dobson F, Hinman R, Hall M, Terwee C, Roos EM, Bennell K. Measurement properties of
589 performance-based measures to assess physical function in hip and knee osteoarthritis: a systematic
590 review. *Osteoarthritis and Cartilage*.20,12,1548-62 (2012)
- 591 42. Dobson F, Hinman R, Roos EM, Abbott J, Stratford P, Davis A, et al. OARSI recommended
592 performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis.
593 *Osteoarthritis and Cartilage*.21,8,1042-52 (2013)
- 594 43. Kroman SL, Roos EM, Bennell KL, Hinman RS, Dobson F. Measurement properties of performance-
595 based outcome measures to assess physical function in young and middle-aged people known to be at
596 high risk of hip and/or knee osteoarthritis: a systematic review. *Osteoarthritis and Cartilage*.22,1,26-39
597 (2014)
- 598 44. Whittaker J, Woodhouse L, Nettel-Aguirre A, Emery C. Outcomes associated with early post-
599 traumatic osteoarthritis and other negative health consequences 3–10 years following knee joint injury
600 in youth sport. *Osteoarthritis and Cartilage*.23,7,1122-9 (2015)
- 601 45. Baltich J, Whittaker J, Von Tscharnner V, Nettel-Aguirre A, Nigg BM, Emery C. The impact of previous
602 knee injury on force plate and field-based measures of balance. *Clinical Biomechanics*.30,8,832-8 (2015)
- 603 46. Whittaker J, Toomey CM, Nettel-Aguirre A, Jaremko JL, Doyle-Baker PK, Woodhouse LJ, et al. Health-
604 related Outcomes following a Youth Sport-related Knee Injury. *Med Sci Sports Exerc*. epub ahead of print
605 (2018)
- 606 47. Moksnes H, Engebretsen L, Eitzen I, Risberg MA. Functional outcomes following a non-operative
607 treatment algorithm for anterior cruciate ligament injuries in skeletally immature children 12 years and
608 younger. A prospective cohort with 2 years follow-up. *Br J Sports Med*.47,8,488-94 (2013)
- 609 48. Moksnes H, Risberg MA. Performance-based functional evaluation of non-operative and operative
610 treatment after anterior cruciate ligament injury. *Scandinavian Journal of Medicine & Science in*
611 *Sports*.19,3,345-55 (2009)
- 612 49. Grindem H, Eitzen I, Moksnes H, Snyder-Mackler L, Risberg MA. A Pair-Matched Comparison of
613 Return to Pivoting Sports at 1 Year in Anterior Cruciate Ligament-Injured Patients After a Nonoperative
614 Versus an Operative Treatment Course. *Am J Sports Med*.40,11,2509-16 (2012)
- 615 50. Logerstedt D, Grindem H, Lynch A, Eitzen I, Engebretsen L, Risberg MA, et al. Single-Legged Hop Tests
616 as Predictors of Self-Reported Knee Function After Anterior Cruciate Ligament Reconstruction The
617 Delaware-Oslo ACL Cohort Study. *Am J Sports Med*.40,10,2348-56 (2012)
- 618 51. Kanko LE, Birmingham TB, Bryant DM, Gillanders K, Lemmon K, Chan R, et al. The star excursion
619 balance test is a reliable and valid outcome measure for patients with knee osteoarthritis. *Osteoarthritis*
620 *and cartilage*.27,4,580-5 (2019)

- 621 52. Gribble PA, Hertel J, Plisky P. Using the Star Excursion Balance Test to assess dynamic postural-
622 control deficits and outcomes in lower extremity injury: a literature and systematic review. *Journal of*
623 *Athletic Training*.47,3,339-57 (2012)
- 624 53. Plisky PJ, Rauh MJ, Kaminski TW, Underwood FB. Star Excursion Balance Test as a predictor of lower
625 extremity injury in high school basketball players. *Journal of Orthopaedic & Sports Physical*
626 *Therapy*.36,12,911-9 (2006)
- 627 54. Herrington L, Hatcher J, Hatcher A, McNicholas M. A comparison of Star Excursion Balance Test reach
628 distances between ACL deficient patients and asymptomatic controls. *The Knee*.16,2,149-52 (2009)
- 629 55. Shaffer SW, Teyhen DS, Lorenson CL, Warren RL, Koreerat CM, Straseske CA, et al. Y-balance test: a
630 reliability study involving multiple raters. *Military Medicine*.178,11,1264-70 (2013)
- 631 56. Hegedus EJ, McDonough SM, Bleakley C, Baxter D, Cook CE. Clinician-friendly lower extremity
632 physical performance tests in athletes: a systematic review of measurement properties and correlation
633 with injury. Part 2—the tests for the hip, thigh, foot and ankle including the star excursion balance test.
634 *Br J Sports Med*.49,10,649-56 (2015)
- 635 57. Jones CJ, Rikli RE. Measuring functional. *The Journal on Active Aging*.1,24-30 (2002)
- 636 58. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in
637 community-residing older adults. *Research Quarterly for Exercise and Sport*.70,2,113-9 (1999)
- 638 59. Rikli RE, Jones CJ. Functional fitness normative scores for community-residing older adults, ages 60-
639 94. *Journal of Aging and Physical Activity*.7,162-81 (1999)
- 640 60. Ekegren CL, Miller WC, Celebrini RG, Eng JJ, Macintyre DL. Reliability and validity of observational risk
641 screening in evaluating dynamic knee valgus. *Journal of Orthopaedic & Sports Physical Therapy*.39,9,665-
642 74 (2009)
- 643 61. Weeks BK, Carty CP, Horan SA. Kinematic predictors of single-leg squat performance: a comparison of
644 experienced physiotherapists and student physiotherapists. *BMC Musculoskeletal Disorders*.13,1,207
645 (2012)
- 646 62. Crossley KM, Zhang W-J, Schache AG, Bryant A, Cowan SM. Performance on the single-leg squat task
647 indicates hip abductor muscle function. *Am J Sports Med*.39,4,866-73 (2011)
- 648 63. Lorenzen K, Zandiyeh P, Whittaker J, Küpper J, Ronsky J, Emery C. Kinetics and kinematics of the knee
649 during a single leg squat 3-10 years after AN intra-articular knee injury sustained while participating in
650 youth sports. *Osteoarthritis and Cartilage*.23,A104 (2015)
- 651 64. Emery CA, Cassidy JD, Klassen TP, Rosychuk RJ, Rowe BH. Development of a clinical static and
652 dynamic standing balance measurement tool appropriate for use in adolescents. *Physical*
653 *Therapy*.85,6,502-14 (2005)
- 654 65. Aandstad A, Holme I, Berntsen S, Anderssen SA. Validity and reliability of the 20 meter shuttle run
655 test in military personnel. *Military Medicine*.176,5,513-8 (2011)
- 656 66. Øiestad BE, Juhl CB, Eitzen I, Thorlund JB. Knee extensor muscle weakness is a risk factor for
657 development of knee osteoarthritis. A systematic review and meta-analysis. *Osteoarthritis and*
658 *Cartilage*.23,2,171-7 (2015)
- 659 67. Chang AH, Chmiel JS, Almagor O, Hayes KW, Guermazi A, Prasad PV, et al. Hip muscle strength and
660 protection against structural worsening and poor function and disability outcomes in knee osteoarthritis.
661 *Osteoarthritis and cartilage*. (2019)
- 662 68. Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. *Osteoarthritis and*
663 *Cartilage*.23,1,22-30 (2015)
- 664 69. Chu CR, Williams AA, Coyle CH, Bowers ME. Early diagnosis to enable early treatment of pre-
665 osteoarthritis. *Arthritis Research & Therapy*.14,3,212 (2012)
- 666 70. Richmond SA, Fukuchi RK, Ezzat A, Schneider K, Schneider G, Emery CA. Are joint injury, sport activity,
667 physical activity, obesity, or occupational activities predictors for osteoarthritis? A systematic review. *J*
668 *Orthop Sports Phys Ther*.43,8,515-B19 (2013)

669 71. Mezhov V, Ciccutini F, Hanna F, Brennan S, Wang Y, Urquhart D, et al. Does obesity affect knee
670 cartilage? A systematic review of magnetic resonance imaging data. *Obesity Reviews*.15,2,143-57 (2014)
671 72. Lim YZ, Wang Y, Wluka AE, Davies-Tuck ML, Hanna F, Urquhart DM, et al. Association of obesity and
672 systemic factors with bone marrow lesions at the knee: a systematic review. *Seminars in Arthritis and*
673 *Rheumatism*.43,5,600-12 (2014)
674 73. Lohmander LS, de Verdier MG, Rollof J, Nilsson PM, Engström G. Incidence of severe knee and hip
675 osteoarthritis in relation to different measures of body mass: a population-based prospective cohort
676 study. *Annals of the Rheumatic Diseases*.68,4,490-6 (2009)
677 74. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, et al. Abdominal visceral and
678 subcutaneous adipose tissue compartments. *Circulation*.116,1,39-48 (2007)
679 75. Visser AW, Ioan-Facsinay A, de Mutsert R, Widya RL, Loeff M, de Roos A, et al. Adiposity and hand
680 osteoarthritis: the Netherlands Epidemiology of Obesity study. *Arthritis Research & Therapy*.16,1,R19
681 (2014)
682 76. Teichtahl AJ, Wang Y, Wluka AE, Szramka M, English DR, Giles GG, et al. The longitudinal relationship
683 between body composition and patella cartilage in healthy adults. *Obesity*.16,2,421-7 (2008)
684 77. Cibere J, Zhang H, Thorne A, Wong H, Singer J, Kopec JA, et al. Association of clinical findings with
685 pre-radiographic and radiographic knee osteoarthritis in a population-based study. *Arthritis Care &*
686 *Research*.62,12,1691-8 (2010)
687 78. Berry P, Wluka A, Davies-Tuck M, Wang Y, Strauss B, Dixon J, et al. The relationship between body
688 composition and structural changes at the knee. *Rheumatology*.49,12,2362-9 (2010)
689 79. Visser A, de Mutsert R, Loeff M, le Cessie S, den Heijer M, Bloem J, et al. The role of fat mass and
690 skeletal muscle mass in knee osteoarthritis is different for men and women: the NEO study.
691 *Osteoarthritis and Cartilage*.22,2,197-202 (2014)
692 80. Ding C, Stannus O, Ciccutini F, Antony B, Jones G. Body fat is associated with increased and lean mass
693 with decreased knee cartilage loss in older adults: a prospective cohort study. *International Journal of*
694 *Obesity*.37,6,822-7 (2013)
695 81. Wang Y, Wluka AE, English DR, Teichtahl AJ, Giles GG, O'Sullivan R, et al. Body composition and knee
696 cartilage properties in healthy, community-based adults. *Annals of the Rheumatic Diseases*.66,9,1244-8
697 (2007)
698 82. Myer GD, Faigenbaum AD, Foss KB, Xu Y, Khoury J, Dolan LM, et al. Injury initiates unfavourable
699 weight gain and obesity markers in youth. *Br J Sports Med*.bjsports-2012-091988 (2013)
700 83. Onat A, Uğur M, Can G, Yüksel H, Hergenç G. Visceral adipose tissue and body fat mass: predictive
701 values for and role of gender in cardiometabolic risk among Turks. *Nutrition*.26,4,382-9 (2010)
702 84. Toomey CM, Whittaker J, Nettel-Aguirre A, reimer RA, Woodhouse LJ, Ghali B, et al. Higher Fat Mass
703 Is Associated With a History of Knee Injury in Youth Sport. *Journal of Orthopaedic & Sports Physical*
704 *Therapy*.47,2,80-7 (2017)
705 85. Miller ME, Rejeski WJ, Reboussin BA, Have TR, Ettinger WH. Physical activity, functional limitations,
706 and disability in older adults. *Journal of the American Geriatrics Society*.48,10,1264-72 (2000)
707 86. Vignon É, Valat J-P, Rossignol M, Avouac B, Rozenberg S, Thoumie P, et al. Osteoarthritis of the knee
708 and hip and activity: a systematic international review and synthesis (OASIS). *Joint Bone Spine*.73,4,442-
709 55 (2006)
710 87. Chmelo E, Nicklas B, Davis C, Miller GD, Legault C, Messier S. Physical activity and physical function in
711 older adults with knee osteoarthritis. *Journal of Physical Activity & Health*.10,6,777-83 (2013)
712 88. Rejeski WJ, Ettinger WH, Jr., Martin K, Morgan T. Treating disability in knee osteoarthritis with
713 exercise therapy: a central role for self-efficacy and pain. *Arthritis Care Res*.11,2,94-101 (1998)
714 89. Hovis KK, Stehling C, Souza RB, Haugom BD, Baum T, Nevitt M, et al. Physical activity is associated
715 with magnetic resonance imaging-based knee cartilage T2 measurements in asymptomatic subjects with
716 and those without osteoarthritis risk factors. *Arthritis & Rheumatism*.63,8,2248-56 (2011)

- 717 90. Lin W, Alizai H, Joseph GB, Srikhun W, Nevitt MC, Lynch JA, et al. Physical activity in relation to knee
718 cartilage T2 progression measured with 3 T MRI over a period of 4 years: data from the Osteoarthritis
719 Initiative. *Osteoarthritis And Cartilage / OARS, Osteoarthritis Research Society*.21,10,1558-66 (2013)
- 720 91. Dunlop DD, Song J, Semanik PA, Sharma L, Bathon JM, Eaton CB, et al. Relation of physical activity
721 time to incident disability in community dwelling adults with or at risk of knee arthritis: prospective
722 cohort study. *BMJ*.348,g2472 (2014)
- 723 92. Santos-Lozano A, Santín-Medeiros F, Cardon G, Torres-Luque G, Bailón R, Bergmeir C, et al. Actigraph
724 GT3X: validation and determination of physical activity intensity cut points. *Int J Sports Med*.34,11,975-
725 82 (2013)
- 726 93. Strath SJ, Kaminsky LA, Ainsworth BE, Ekelund U, Freedson PS, Gary RA, et al. Guide to the
727 assessment of physical activity: Clinical and research applications: a scientific statement from the
728 American Heart Association. *Circulation*.128,20,2259-79 (2013)
- 729 94. Butte NF, Ekelund U, Westerterp KR. Assessing Physical Activity Using Wearable Monitors: Measures
730 of Physical Activity. *Medicine and Science in Sports and Exercise*.44,1 Suppl 1,S5-S12 (2012)
- 731 95. Ahn GE, Song J, Lee J, Semanik PA, Chang RW, Sharma L, et al. **Relationship of Objective to Self-**
732 **Reported Physical Activity Measures Among Adults in the Osteoarthritis Initiative.** Abstract. Arthritis
733 and Rheumatism 2012. 64. p. S104-S5
- 734 96. Christensen R, Astrup A, Bliddal H. Weight loss: the treatment of choice for knee osteoarthritis? A
735 randomized trial. *Osteoarthritis and Cartilage*.13,1,20-7 (2005)
- 736 97. Bartels E, Christensen R, Christensen P, Henriksen M, Bennett A, Gudbergson H, et al. Effect of a 16
737 weeks weight loss program on osteoarthritis biomarkers in obese patients with knee osteoarthritis: a
738 prospective cohort study. *Osteoarthritis and Cartilage*.22,11,1817-25 (2014)
- 739 98. Zheng H, Chen C. Body mass index and risk of knee osteoarthritis: systematic review and meta-
740 analysis of prospective studies. *BMJ Open*.5,12,e007568 (2015)
- 741 99. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed
742 with knee osteoarthritis: a systematic review and meta-analysis. *Ann Rheum Dis*.66,4,433-9 (2007)
- 743 100. Dai Z, Niu J, Zhang Y, Jacques P, Felson DT. Dietary intake of fibre and risk of knee osteoarthritis in
744 two US prospective cohorts. *Ann Rheum Dis*.76,8,1411-9 (2017)
- 745 101. Ameye LG, Chee WS. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a
746 systematic review of the scientific evidence. *Arthritis Research & Therapy*.8,4,R127 (2006)
- 747 102. Sanghi D, Mishra A, Sharma AC, Raj S, Mishra R, Kumari R, et al. Elucidation of Dietary Risk Factors in
748 Osteoarthritis Knee—A Case-Control Study. *Journal of the American College of Nutrition*.34,1,15-20
749 (2015)
- 750 103. Subar AF, Kirkpatrick SI, Mittl B, Zimmerman TP, Thompson FE, Bingley C, et al. The Automated Self-
751 Administered 24-hour dietary recall (ASA24): a resource for researchers, clinicians, and educators from
752 the National Cancer Institute. *J Acad Nutr Diet*.112,8,1134-7 (2012)
- 753 104. Schröder H, MEstruch, RMartínez-González, MA Corella, D Salas-Salvadó, J Lamuela-Raventós, R
754 Ros, E Salaverria, IFiol, M Lapetra, J Vinyoles, E Gómez-Gracia, E Lahoz, C Serra-Majem, L Pintó, X Ruiz-
755 Gutierrez, VCovas, MI. A short screener is valid for assessing Mediterranean diet adherence among older
756 Spanish men and women. *J Nutr*.141,6,1140-5 (2011)
- 757 105. Sturnieks DL, Besier TF, Mills PM, Ackland TR, Maguire KF, Stachowiak GW, et al. Knee joint
758 biomechanics following arthroscopic partial meniscectomy. *Journal of Orthopaedic Research*.26,8,1075-
759 80 (2008)
- 760 106. Gardinier ES, Manal K, Buchanan TS, Snyder-Mackler L. Altered loading in the injured knee after ACL
761 rupture. *Journal of Orthopaedic Research*.31,3,458-64 (2013)
- 762 107. Haughom BD, Souza R, Schairer WW, Li X, Ma CB. Evaluating rotational kinematics of the knee in
763 ACL-ruptured and healthy patients using 3.0 Tesla magnetic resonance imaging. *Knee Surgery, Sports*
764 *Traumatology, Arthroscopy*.20,4,663-70 (2012)

765 108. Waite J, Beard D, Dodd C, Murray D, Gill H. In vivo kinematics of the ACL-deficient limb during
766 running and cutting. *Knee Surgery, Sports Traumatology, Arthroscopy*.13,5,377-84 (2005)

767 109. Zhang L-Q, Shiavi RG, Limbird TJ, Minorik JM. Six degrees-of-freedom kinematics of ACL deficient
768 knees during locomotion—compensatory mechanism. *Gait & posture*.17,1,34-42 (2003)

769 110. Noyes FR, Schipplein OD, Andriacchi TP, Saddemi SR, Weise M. The anterior cruciate ligament-
770 deficient knee with varus alignment An analysis of gait adaptations and dynamic joint loadings. *Am J*
771 *Sports Med*.20,6,707-16 (1992)

772 111. Hubley-Kozey C, Deluzio K, Landry S, McNutt J, Stanish W. Neuromuscular alterations during walking
773 in persons with moderate knee osteoarthritis. *Journal of Electromyography and Kinesiology*.16,4,365-78
774 (2006)

775 112. Heiden TL, Lloyd DG, Ackland TR. Knee joint kinematics, kinetics and muscle co-contraction in knee
776 osteoarthritis patient gait. *Clinical Biomechanics*.24,10,833-41 (2009)

777 113. Mündermann A, Dyrby CO, Andriacchi TP. Secondary gait changes in patients with medial
778 compartment knee osteoarthritis: increased load at the ankle, knee, and hip during walking. *Arthritis &*
779 *Rheumatism*.52,9,2835-44 (2005)

780 114. Rudolph KS, Schmitt LC, Lewek MD. Age-related changes in strength, joint laxity, and walking
781 patterns: are they related to knee osteoarthritis? *Physical Therapy*.87,11,1422-32 (2007)

782 115. Hortobágyi T, Westerkamp L, Beam S, Moody J, Garry J, Holbert D, et al. Altered hamstring-
783 quadriceps muscle balance in patients with knee osteoarthritis. *Clinical Biomechanics*.20,1,97-104 (2005)

784 116. Benedetti M, Catani F, Bilotta T, Marcacci M, Mariani E, Giannini S. Muscle activation pattern and
785 gait biomechanics after total knee replacement. *Clinical Biomechanics*.18,9,871-6 (2003)

786 117. Kuntze G, von Tscharnner V, Hutchison C, Ronsky JL. Alterations in lower limb multimuscle activation
787 patterns during stair climbing in female total knee arthroplasty patients. *Journal of*
788 *Neurophysiology*.114,5,2718-25 (2015)

789 118. Kuntze G, von Tscharnner V, Hutchison C, Ronsky J. Multi-muscle activation strategies during walking
790 in female post-operative total joint replacement patients. *Journal of Electromyography and*
791 *Kinesiology*.25,4,715-21 (2015)

792 119. Cicuttini F, Wluka A, Hankin J, Wang Y. Longitudinal study of the relationship between knee angle
793 and tibiofemoral cartilage volume in subjects with knee osteoarthritis. *Rheumatology*.43,3,321-4 (2004)

794 120. Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunlop DD. The role of knee alignment in disease
795 progression and functional decline in knee osteoarthritis. *JAMA*.286,2,188-95 (2001)

796 121. Wikstrom EA, Tillman MD, Chmielewski TL, Borsa PA. Measurement and evaluation of dynamic joint
797 stability of the knee and ankle after injury. *Sports Medicine*.36,5,393-410 (2006)

798 122. Riemann BL, Lephart SM. The sensorimotor system, part II: the role of proprioception in motor
799 control and functional joint stability. *Journal of Athletic Training*.37,1,80-4 (2002)

800 123. Williams GN, Buchanan TS, Barrance PJ, Axe MJ, Snyder-Mackler L. Quadriceps weakness, atrophy,
801 and activation failure in predicted noncopers after anterior cruciate ligament injury. *Am J Sports*
802 *Med*.33,3,402-7 (2005)

803 124. Suter E, Herzog W. Does Muscle Inhibition after Knee Injury Increase the Risk of Osteoarthritis?
804 *Exercise and Sport Sciences Reviews*.28,1,15-8 (2000)

805 125. Hurley MV. The role of muscle weakness in the pathogenesis of osteoarthritis. *Rheumatic Disease*
806 *Clinics of North America*.25,2,283-98 (1999)

807 126. Bennell KL, Hunt MA, Wrigley TV, Lim B-W, Hinman RS. Role of muscle in the genesis and
808 management of knee osteoarthritis. *Rheumatic Disease Clinics of North America*.34,3,731-54 (2008)

809 127. Roos EM, Herzog W, Block JA, Bennell KL. Muscle weakness, afferent sensory dysfunction and
810 exercise in knee osteoarthritis. *Nature Reviews Rheumatology*.7,1,57-63 (2011)

811 128. Van de Velde SK, Bingham JT, Hosseini A, Kozanek M, DeFrate LE, Gill TJ, et al. Increased
812 tibiofemoral cartilage contact deformation in patients with anterior cruciate ligament deficiency.
813 *Arthritis & Rheumatism*.60,12,3693-702 (2009)

814 129. Liu F, Kozanek M, Hosseini A, Van de Velde SK, Gill TJ, Rubash HE, et al. In vivo tibiofemoral cartilage
815 deformation during the stance phase of gait. *Journal of Biomechanics*.43,4,658-65 (2010)

816 130. Gardinier ES, Di Stasi S, Manal K, Buchanan TS, Snyder-Mackler L. Knee contact force asymmetries in
817 patients who failed return-to-sport readiness criteria 6 months after anterior cruciate ligament
818 reconstruction. *Am J Sports Med*.42,12,2917-25 (2014)

819 131. Gardinier ES, Manal K, Buchanan TS, Snyder-Mackler L. Clinically-relevant measures associated with
820 altered contact forces in patients with anterior cruciate ligament deficiency. *Clinical*
821 *Biomechanics*.29,5,531-6 (2014)

822 132. Andriacchi TP, Favre J, Erhart-Hledik J, Chu CR. A systems view of risk factors for knee osteoarthritis
823 reveals insights into the pathogenesis of the disease. *Annals of Biomedical Engineering*.43,2,376-87
824 (2015)

825 133. Gardiner BS, Woodhouse FG, Besier TF, Grodzinsky AJ, Lloyd DG, Zhang L, et al. Predicting Knee
826 Osteoarthritis. *Annals of Biomedical Engineering*.1-12 (2015)

827 134. Kobsar D, Osis ST, Phinyomark A, Boyd JE, Ferber R. Reliability of gait analysis using wearable
828 sensors in patients with knee osteoarthritis. *Journal of Biomechanics*.49,16,3977-82 (2016)

829 135. Kobsar D, Osis ST, Boyd JE, Hettinga BA, Ferber R. Wearable sensors to predict improvement
830 following an exercise intervention in patients with knee osteoarthritis. *Journal of Neuroengineering and*
831 *Rehabilitation*.14,1,94 (2017)

832 136. Tadano S, Takeda R, Sasaki K, Fujisawa T, Tohyama H. Gait characterization for osteoarthritis
833 patients using wearable gait sensors (H-Gait systems). *Journal of Biomechanics*.49,5,684-90 (2016)

834 137. Sutter EG, Widmyer MR, Utturkar GM, Spritzer CE, Garrett WE, Jr., DeFrate LE. In vivo measurement
835 of localized tibiofemoral cartilage strains in response to dynamic activity. *Am J Sports Med*.43,2,370-6
836 (2015)

837 138. Chehab EF, Favre J, Erhart-Hledik JC, Andriacchi TP. Baseline knee adduction and flexion moments
838 during walking are both associated with 5 year cartilage changes in patients with medial knee
839 osteoarthritis. *Osteoarthritis and Cartilage*.22,11,1833-9 (2014)

840 139. Walter JP, Kinney AL, Banks SA, D'Lima DD, Besier TF, Lloyd DG, et al. Muscle synergies may improve
841 optimization prediction of knee contact forces during walking. *Journal of Biomechanical*
842 *Engineering*.136,2,021031 (2014)

843 140. Gerus P, Sartori M, Besier TF, Fregly BJ, Delp SL, Banks SA, et al. Subject-specific knee joint geometry
844 improves predictions of medial tibiofemoral contact forces. *Journal of Biomechanics*.46,16,2778-86
845 (2013)

846 141. Johnson WR, Alderson J, Lloyd DG, Mian A. Predicting Athlete Ground Reaction Forces and
847 Moments from Spatio-temporal Driven CNN Models. *IEEE Transactions on Biomedical Engineering*.Early
848 Access (2018)

849 142. Long MJ, Papi E, Duffell LD, McGregor AH. Predicting knee osteoarthritis risk in injured populations.
850 *Clinical biomechanics*.47,87-95 (2017)

851 143. Pfeiffer S, Harkey M, Stanley L, Blackburn J, Padua D, Spang J, et al. Associations Between Slower
852 Walking Speed and T1p Magnetic Resonance Imaging of Femoral Cartilage Following Anterior Cruciate
853 Ligament Reconstruction. *Arthritis Care Res*.70,8,1132-40 (2018)

854 144. Chu CR, Sheth S, Erhart-Hledik J, Do B, Titchenal M, Andriacchi T. Mechanically stimulated
855 biomarkers signal cartilage changes over 5 years consistent with disease progression in medial knee
856 osteoarthritis patients. *J Orthop Res*.36,3,891-7 (2018)

857 145. Pietrosimone B, Loeser R, Blackburn J, Padua D, Harkey M, Stanley L, et al. Biochemical markers of
858 cartilage metabolism are associated with walking biomechanics 6-months following anterior cruciate
859 ligament reconstruction. *J Orthop Res*.35,10,2288-97 (2017)

860 146. Favre J, Erhart-Hledik J, Chehab E, Andriacchi T. Baseline ambulatory knee kinematics are associated
861 with changes in cartilage thickness in osteoarthritic patients over 5 years. *J Biomech*.49,9,1859-64 (2016)

862 147. Erhart-Hledik J, Favre J, Asay J, Smith R, Giori N, Mündermann A, et al. A relationship between
863 mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in
864 cartilage thickness after 5 years. *Osteoarthritis Cartilage*.20,11,1309-15 (2012)

865 148. Hayashi D, Roemer F, Guermazi A. Recent advances in research imaging of osteoarthritis with focus
866 on MRI, ultrasound and hybrid imaging. *Clin Exp Rheumatol*.36,Suppl 114,43-52 (2018)

867 149. Hayashi D, Roemer FW, Guermazi A. Imaging of osteoarthritis—recent research developments and
868 future perspective. *The British journal of radiology*.91,1085,20170349 (2018)

869 150. Brandt KD, Fife RS, Braunstein EM, Katz B. Radiographic grading of the severity of knee
870 osteoarthritis: relation of the Kellgren and Lawrence grade to a grade based on joint space narrowing,
871 and correlation with arthroscopic evidence of articular cartilage degeneration. *Arthritis &*
872 *Rheumatism*.34,11,1381-6 (1991)

873 151. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Annals of the Rheumatic*
874 *Diseases*.16,4,494-502 (1957)

875 152. Wirth W, Duryea J, Hellio Le Graverand MP, John MR, Nevitt M, Buck RJ, et al. Direct comparison of
876 fixed flexion, radiography and MRI in knee osteoarthritis: responsiveness data from the Osteoarthritis
877 Initiative. *Osteoarthritis Cartilage*.21,1,117-25 (2013)

878 153. Guermazi A, Niu JB, Hayashi D, Roemer FW, Englund M, Neogi T, et al. Prevalence of abnormalities
879 in knees detected by MRI in adults without knee osteoarthritis: population based observational study
880 (Framingham Osteoarthritis Study). *British Medical Journal*.345,e5339 (2012)

881 154. Hunter DJ, Guermazi A, Lo GH, Grainger AJ, Conaghan PG, Boudreau RM, et al. Evolution of semi-
882 quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis Knee Score). *Osteoarthritis*
883 *and Cartilage*.19,8,990-1002 (2011)

884 155. Sharma L, Guermazi A, Almagor O, Crema M, Dunlop DD, Roemer F, et al. **Tissue Lesions in**
885 **Osteoarthritis Initiative Participants with Normal X-Rays and Risk Factors for Incident Cartilage**
886 **Damage**. Abstract. Arthritis and Rheumatism Annual Scientific Meeting of the American College of
887 Rheumatology and Association of Rheumatology Health Professionals; Washington, DC, United States:
888 John Wiley and Sons Inc. ; 2012. S1039-S40

889 156. Su F, Hilton JF, Nardo L, Wu S, Liang F, Link TM, et al. Cartilage morphology and T 1 and T 2
890 quantification in ACL-reconstructed knees: a 2-year follow-up. *Osteoarthritis and Cartilage*.21,8,1058-67
891 (2013)

892 157. Van Ginckel A, Verdonk P, Witvrouw E. Cartilage adaptation after anterior cruciate ligament injury
893 and reconstruction: implications for clinical management and research? A systematic review of
894 longitudinal MRI studies. *Osteoarthritis and Cartilage*.21,8,1009-24 (2013)

895 158. Hunter DJ, Lohmander LS, Makovey J, Tamez-Peña J, Totterman S, Schreyer E, et al. The effect of
896 anterior cruciate ligament injury on bone curvature: exploratory analysis in the KANON trial.
897 *Osteoarthritis and cartilage*.22,7,959-68 (2014)

898 159. Neogi T, Felson DT. Osteoarthritis: Bone as an imaging biomarker and treatment target in OA.
899 *Nature Reviews Rheumatology*.12,9,503-4 (2016)

900 160. Bowes M, Lohmander L, Wolstenholme C, Vincent G, Conaghan P, Frobell R. Marked and rapid
901 change of bone shape in acutely ACL injured knees—an exploratory analysis of the KANON trial.
902 *Osteoarthritis Cartilage*.27,638-45 (2019)

903 161. Hunter DJ, Arden N, Conaghan PG, Eckstein F, Gold G, Grainger A, et al. Definition of osteoarthritis
904 on MRI: results of a Delphi exercise. *Osteoarthritis and Cartilage*.19,8,963-9 (2011)

905 162. Schiphof D, Oei E, Hofman A, Waarsing J, Weinans H, Bierma-Zeinstra S. Sensitivity and associations
906 with pain and body weight of an MRI definition of knee osteoarthritis compared with radiographic
907 Kellgren and Lawrence criteria: a population-based study in middle-aged females. *Osteoarthritis and*
908 *Cartilage*.22,3,440-6 (2014)

909 163. Culvenor AG, Collins NJ, Guermazi A, Cook JL, Vicenzino B, Khan KM, et al. Early knee osteoarthritis
910 is evident one year following anterior cruciate ligament reconstruction: a magnetic resonance imaging
911 evaluation. *Arthritis & Rheumatology*.67,4,946-55 (2015)

912 164. Roemer FW, Englund M, Turkiewicz A, Struglics A, Guermazi A, Lohmander LS, et al. Molecular and
913 Structural Biomarkers of Inflammation at Two Years After Acute Anterior Cruciate Ligament Injury Do
914 Not Predict Structural Knee Osteoarthritis at Five Years. *Arthritis & Rheumatology*.71,2,238-43 (2019)

915 165. Hunter D, Altman R, Cicuttini F, Crema M, Duryea J, Eckstein F, et al. OARSI Clinical Trials
916 Recommendations: Knee imaging in clinical trials in osteoarthritis. *Osteoarthritis and Cartilage*.23,5,698-
917 715 (2015)

918 166. Roemer FW, Frobell R, Lohmander LS, Niu J, Guermazi A. Anterior Cruciate Ligament OsteoArthritis
919 Score (ACLOAS): longitudinal MRI-based whole joint assessment of anterior cruciate ligament injury.
920 *Osteoarthritis and cartilage*.22,5,668-82 (2014)

921 167. Guermazi A, Roemer FW, Hayashi D, Crema MD, Niu J, Zhang Y, et al. Assessment of synovitis with
922 contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high
923 risk of, knee osteoarthritis: the MOST study. *Annals of the Rheumatic Diseases*.70,5,805-11 (2011)

924 168. Magnusson K, Kumm J, Turkiewicz A, Englund M. A naturally aging knee, or development of early
925 knee osteoarthritis? *Osteoarthritis and cartilage*.26,11,1447-52 (2018)

926 169. Baert IA, Staes F, Truijien S, Mahmoudian A, Noppe N, Vanderschueren G, et al. Weak associations
927 between structural changes on MRI and symptoms, function and muscle strength in relation to knee
928 osteoarthritis. *Knee Surgery, Sports Traumatology, Arthroscopy*.22,9,2013-25 (2014)

929 170. Neogi T, Felson D, Niu J, Nevitt M, Lewis CE, Aliabadi P, et al. Association between radiographic
930 features of knee osteoarthritis and pain: results from two cohort studies. *Bmj*.339,b2844 (2009)

931 171. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of
932 osteoarthritis and risk stratification for clinical trials and clinical use. *Osteoarthritis and*
933 *Cartilage*.23,8,1233-41 (2015)

934 172. Bruyère O, Genant H, Kothari M, Zaim S, White D, Peterfy C, et al. Longitudinal study of magnetic
935 resonance imaging and standard X-rays to assess disease progression in osteoarthritis. *Osteoarthritis and*
936 *Cartilage*.15,1,98-103 (2007)

937 173. Hayashi D, Felson D, Niu J, Hunter D, Roemer F, Aliabadi P, et al. Pre-radiographic osteoarthritic
938 changes are highly prevalent in the medial patella and medial posterior femur in older persons:
939 Framingham OA study. *Osteoarthritis and Cartilage*.22,1,76-83 (2014)

940 174. Englund M, Guermazi A, Gale D, Hunter DJ, Aliabadi P, Clancy M, et al. Incidental meniscal findings
941 on knee MRI in middle-aged and elderly persons. *New England Journal of Medicine*.359,11,1108-15
942 (2008)

943 175. Felson D, Lohmander L. Whither osteoarthritis biomarkers? *Osteoarthritis and cartilage/OARS,*
944 *Osteoarthritis Research Society*.17,4,419 (2009)

945 176. Bay-Jensen AC, Thudium CS, Mobasheri A. Development and use of biochemical markers in
946 osteoarthritis: current update. *Current Opinion in Rheumatology*.30,1,121-8 (2017)

947 177. Ling SM, Patel DD, Garner P, Zhan M, Vaduganathan M, Muller D, et al. Serum protein signatures
948 detect early radiographic osteoarthritis. *Osteoarthritis and Cartilage*.17,1,43-8 (2009)

949 178. Golightly YM, Marshall SW, Kraus VB, Renner JB, Villaveces A, Casteel C, et al. 124 Serum Cartilage
950 Oligomeric Matrix Protein Hyaluronan High-Sensitivity C-Reactive Protein and Keratan Sulfate as
951 Predictors of Incident Radiographic Knee Osteoarthritis: Differences by Chronic Knee Symptoms.
952 *Osteoarthritis and Cartilage*.18,S62-S3 (2010)

953 179. Blumenfeld O, Williams FM, Hart DJ, Spector TD, Arden N, Livshits G. Association between cartilage
954 and bone biomarkers and incidence of radiographic knee osteoarthritis (RKO) in UK females: a
955 prospective study. *Osteoarthritis Cartilage*.21,7,923-9 (2013)

- 956 180. Sowers M, Lachance L, Jamadar D, Hochberg MC, Hollis B, Crutchfield M, et al. The associations of
957 bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and
958 perimenopausal women. *Arthritis Rheum.*42,3,483-9 (1999)
- 959 181. Kosinska MK, Liebisch G, Lochnit G, Wilhelm J, Klein H, Kaesser U, et al. Sphingolipids in Human
960 Synovial Fluid: A Lipidomic Study. *PLOS One.*9,3,e91769 (2014)
- 961 182. Adams S, Setton LA, Kensicki E, Bolognesi MP, Toth AP, Nettles DL. Global metabolic profiling of
962 human osteoarthritic synovium. *Osteoarthritis and Cartilage.*20,1,64-7 (2012)
- 963 183. Bauer D, Hunter D, Abramson S, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis
964 biomarkers: a proposed approach. *Osteoarthritis and Cartilage.*14,8,723-7 (2006)
- 965 184. Kraus VB, Blanco F, Englund M, Henrotin Y, Lohmander L, Losina E, et al. OARSI Clinical Trials
966 Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. *Osteoarthritis and*
967 *cartilage.*23,5,686-97 (2015)
- 968 185. Van Spil W, DeGroot J, Lems W, Oostveen J, Lafeber F. Serum and urinary biochemical markers for
969 knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. *Osteoarthritis*
970 *and cartilage.*18,5,605-12 (2010)
- 971 186. (FDA) SSMUFaDA. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet] 2016.
972 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK326791/?report=reader>
- 973 187. van der Elst K, Meyfroidt S, De Cock D, De Groef A, Binnard E, Moons P, et al. Unraveling Patient-
974 Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative
975 Study. *Arthritis Care Res (Hoboken).*68,9,1278-87 (2016)

976 **Acknowledgements**

977 The authors acknowledge the financial support of Alberta Team OA (Alberta Innovates Health Solutions
978 Collaborative Research and Innovation Opportunity Team) and Arthritis Research UK who funded an initial
979 meeting at Osteoarthritis Research Society International in April 2015 to discuss outcomes in early OA.
980 The support of the Osteoarthritis Research Society International is acknowledged for meeting room
981 facilities. The authors would like to thank Tanya Childs for the administrative support in completing this
982 manuscript.

983 **Author contributions**

984 “CAE, JLW, NKA, AMa, LSL, EMR, KLB, CMT, RAR, DT, JLR, GK, DGL, TA, ME, VBK, EL, SBZ, JR, GP, FPL, LSM,
985 MAR, AMo, AG, DJH, NKA researched data for the article. CAE, JLW, NKA, AMa, LSL, EMR, KLB, CMT, RAR,
986 DT, JLR, GK, DGL, TA, ME, VBK, EL, SBZ, JR, GP, FPL, LSM, MAR, AMo, AG, DJH, NKA provided substantial
987 contributions to discussion of content. CAE, JLW, NKA, AMa, LSL, and FPL wrote the article and CAE, JLW,
988 NKA, AMa, LSL, EMR, KLB, CMT, RAR, DT, JLR, GK, DGL, TA, ME, VBK, EL, SBZ, JR, GP, FPL, LSM, MAR, AMo,
989 AG, DJH, NKA reviewed and/or edited the manuscript before submission.”

990 **Competing Interests**

991 CAE, JLW, AMa, NKA, KLB, CMT, RAR, DT, JLR, GK, DGL, TA, ME, VBK, EL, SBZ, JR, GP, FPL, LSM, MAR, AM,
992 declare that they have no competing interests. E.M.R. and L.S.L declare that they contributed to the
993 development of the Knee Injury and Osteoarthritis Outcome Score (KOOS). L.S.L. also declares that he
994 contributed to the development of the ICOAP and the Anterior Cruciate Ligament Osteoarthritis Score (ACLOAS).
995 AG is Consultant to Pfizer, TissueGene, AstraZeneca and Merck Serono. He is Shareholder of BICL, LLC. DJH is a
996 Consultant to Pfizer, TissueGene, TLCBio and Merck Serono and contributed to the development of MOAKS.

997 Related links

998 KOOS scoring instructions: <http://www.koos.nu/>

999 Single Leg Hop for distance: <https://www.sralab.org/rehabilitation-measures/single-limb-hop-tests>

1000 30-second Chair Sit-to-Stand Test: <https://vimeo.com/74649743>

1001 6-minute walk test: <https://vimeo.com/74649737>

Box 1. Proposed outcomes for the assessment of early pre-radiographic OA

Below we provide suggestions for outcomes measures that could be used to assess individuals with early pre-radiographic OA in clinical practice and in research settings. Further research is needed, including evaluation of validity of early-OA specific outcomes and change in outcomes with progression of OA as many of these measures have been evaluated primarily in established OA^{43, 44, 47-50, 57-59, 66, 153}.

In clinical practice and research settings:

Patient-reported outcomes

The Knee Injury and Osteoarthritis Outcome Score (KOOS) can be used to measure pain during activity, other symptoms (e.g., stiffness, grinding, catching, swelling, knee flexion and extension, function in daily life and during sport and recreational activities, and quality of life across different age and treatment groups. The intermittent and constant assessment of pain score (ICOAP) can evaluate constant and intermittent pain

Clinical examination

A clinical assessment including joint line tenderness should be performed on individuals with newly-onset symptoms of knee pain, stiffness, crepitus, or a feeling of ‘giving way’.

Functional outcomes

Three measures seem promising for use in clinical settings on the basis of their reproducibility, patient acceptability and the equipment¹⁵³ and expertise required: Single leg hop test^{43, 44, 47-50}, 30 second chair sit-to-stand⁵⁷⁻⁵⁹, Star Excursion Balance Test^{44, 51-56} and quadriceps strength measure^{44, 47, 48, 52, 66}. Multiple additional functional measures have been validated for use in research settings.

Lifestyle-related outcomes

Adiposity can be assessed by body fat percentage or fat mass index (fat mass/height²) using dual-energy x-ray absorptiometry or bioelectrical impedance analysis if available. BMI is more feasible in clinical settings, although has limitations for use in athletes. Levels of physical activity can be assessed using a validated physical activity monitor or a validated questionnaire if objective methods are not available. Nutrition outcomes are not currently suggested for use in routine clinical care, however the 3-day dietary record provides reliable estimates of nutrient intake.

In research settings only:

Biomechanical outcomes

Measures of biomechanical outcomes require further research and are not currently suggested for use in routine clinical care. However, such outcomes are ideal for informing the underlying mechanisms of OA progression and informing treatment interventions in research setting.

Imaging outcomes

The utility of plain radiography in early OA is limited. Although MRI has superior sensitivity to change and validity in the context of early OA¹⁵³, and is hence ideal in research settings, MRI is not thought appropriate for the routine clinical care setting because of the high cost and potential risk of over-diagnosis.

Biomarkers

No biomarkers are currently of use in routine clinical care; however, further validation of proteomic, lipidomic and metabolomic tools in research settings could lead to informative cartilage and synovial fluid profiles and provide important insights into OA progression.

1003
1004

Table 1. Important physical function outcomes

Outcome measure	Test measure	Equipment Required	Reliability			Error	Validity		Responsive /Interpretability	Appropriate risk group (age)	References
			Intra	Inter	Re-test		Structural	Ho testing			
Single leg hop for distance	Length (cm)	Measuring tape	+	-	-	-	-	+/-	-	Post-trauma (≤45 years)	1005 43, 44, 47-50 1006
Cross hop for distance	Length (cm)	Measuring tape	+	-	-	-	-	+/-	-	Post-trauma (≤45 years)	43, 47-50 1007 1008
6 meter timed hop test	Time (sec)	Measuring tape	+	-	-	-	-	+	-	Post-trauma (≤45 years)	43, 47-50 1009
Star excursion balance test	Length (% leg length)	Measuring mat, tape and skilled rater (leg length)	+	+	+	+	-	+	-	Post-trauma or obese (all ages)	44, 51-56 1010
30-second chair sit-to-stand test	Count (# repetitions)	Chair and timer	+	+	-	-	-	-	-	Post-trauma or obese (all ages)	57-59
6 minute walk test	Length (m)	Flat 20m walking area, timer and chair	-	-	-	-	-	-	-	Obese (all ages)	41, 42
Vertical drop jump	Risk rating	31cm high box	+	+	-	-	-	+/-	-	Post-trauma (≤45 years)	44, 60
Single leg squat	Risk rating	None	+	+	-	-	+/-	+/-	-	Post-trauma or obese (all ages)	44, 61-63
Unipedal dynamic balance	Time (sec)	Balance pad and timer	-	+	+	-	+	+	-	Post-trauma or obese (all ages)	44, 64
20 meter shuttle run	Stage	Coloured tape and instructions.	-	-	+	+	-/+	+	-	Post-trauma (≤45 years)	44, 65
Quadriceps strength	Force (Nm/Kg)	Hand-held or isokinetic dynamometer and skilled rater	+	+	+	+	+	+	+	Post-trauma or obese (all ages)	44, 47, 48, 52, 66
Hamstring strength	Force (Nm/Kg)	Hand-held or isokinetic dynamometer	+	+	+	+	+/-	+/-	+/-	Post-trauma or obese (all ages)	41, 43, 67
Hip adductor or hip abductor strength	Force (Nm/Kg)	Hand-held or isokinetic dynamometer	+	+	+	+	-	+/-	-	Post-trauma or obese (all ages)	41, 43, 67

+ =

1011

supporting evidence, - = no supporting evidence, +/- = conflicting evidence

1012

1013

Box 2. MRI Defined Osteoarthritis (Hunter et al 2011)¹⁶¹

A definition of tibiofemoral osteoarthritis on MRI would be the presence of both group [A] features or one group [A] feature and two or more group [B] features

Group [A] after exclusion of joint trauma within the last 6 months (by history) and exclusion of inflammatory arthritis (by radiographs, history and laboratory parameters):

- i) Definite osteophyte formation*
- ii) Full thickness cartilage loss

Group [B]:

- i) Subchondral bone marrow lesion or cyst not associated with meniscal or ligamentous attachments
- ii) Meniscal subluxation, maceration or degenerative (horizontal) tear
- iii) Partial thickness cartilage loss (where full thickness loss is not present)
- iv) Bone attrition

A definition of patellofemoral OA requires all of the following involving the patella and/or anterior femur:

- i) A definite osteophyte*
- ii) Partial or full thickness cartilage loss

1014

1015 * The definition of a 'definite osteophyte' was not delineated in the Delphi process and requires further
1016 validation.